Articles

Read More ›

Read More ›

Read More ›

In this interview, Martee Hensley, MD, a medical oncologist practicing at Memorial Sloan Kettering Cancer Center, commented on the introduction of trabectedin as a treatment alternative for women with uterine leiomyosarcoma. Read More ›

Read More ›

The French SIGNAL and PHARE projects have collected data on more than 9800 patients with breast cancer since 2006. In evaluating the outcomes of sequential and concomitant administration of trastuzumab within this cohort, this study provides insight into the ideal administration protocol for patients with human epidermal growth factor receptor 2–positive (HER2+) breast cancer. Read More ›

The 21-gene Recurrence Score® is the result of a commercial genomic test that evaluates the likelihood that breast cancer will recur, and the likely benefit from chemotherapy and/or radiation therapy. This study evaluates disparities in hormone receptor–positive (HR+) breast cancer outcome by age and 21-gene Recurrence Score®. Read More ›

Previous studies have reported that an elevated neutrophil-to-lymphocyte ratio is associated with an increased risk of relapse and worse survival in women with breast cancer. Additional data about the prognostic role for this biomarker in patients with early breast cancer are presented here. Read More ›

In this ongoing phase 2 study, postmenopausal women with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) breast cancer are being treated with abemaciclib (a selective inhibitor of cyclin-dependent kinases 4 and 6), anastrozole (an aromatase inhibitor), or both simultaneously. Read More ›

Read More ›